Blood thinner and aspirin show similar bleeding risk in coronary patients

March 20, 2017 by Amara Omeokwe, Duke University
Credit: Duke University

Substituting rivaroxaban for aspirin in patients with acute coronary syndromes (ACS) appears to cause no significant increase in bleeding risk, according to a study led by scientists from the Duke Clinical Research Institute (DCRI) and Harvard Medical School.

The findings of the Phase 2 GEMINI ACS 1 study—presented Saturday at the American College of Cardiology 66th Annual Scientific Session in Washington, D.C., and simultaneously published in the journal The Lancet—are based on a randomized study of 3,037 patients with ACS.

Acute coronary syndrome is characterized by reduced blood flow to the heart, including heart attack or unstable angina. Standard treatment includes a regimen of and antiplatelet drugs such as ticagrelor or clopidogrel. Some patients, however, cannot tolerate aspirin, and for others, the dual therapy doesn't prevent complications.

"We wanted to examine if we could substitute a blood thinner for aspirin in the standard regimen and achieve better or similar outcomes. If so, it could open up new treatment avenues," said E. Magnus Ohman, the study's co-lead author and member of the DCRI. Ohman and Michael Gibson, M.D., of Harvard Medical School, led the study.

Study patients were randomly assigned to take either rivaroxaban or aspirin in addition to an antiplatelet drug within 10 days of presenting with ACS. The therapy was continued for six to 12 months.

Researchers sought to determine whether rivaroxaban caused more than aspirin as a component of the dual therapy. They found no statistically significant difference in bleeding rates among the rivaroxaban group (5.3 percent) and the aspirin group (4.9 percent).

"This study is important because it is the first where aspirin has been removed within the first few days after experienced ACS and replaced with another anti-clotting drug," Ohman said. "Finding that bleeding profiles were the same in both study groups is an exciting first step towards expanding post-ACS treatment."

Ohman noted that the trial was exploratory and further studies are needed to evaluate how the regimens compare in preventing stroke, and death.

Explore further: New blood thinner better at preventing recurrent blood clots than aspirin

More information: E Magnus Ohman et al. Clinically significant bleeding with low-dose rivaroxaban versus aspirin, in addition to P2Y12 inhibition, in acute coronary syndromes (GEMINI-ACS-1): a double-blind, multicentre, randomised trial, The Lancet (2017). DOI: 10.1016/S0140-6736(17)30751-1

Related Stories

New blood thinner better at preventing recurrent blood clots than aspirin

March 19, 2017
An international research team with prominent Canadian leadership has found that the blood thinner rivaroxaban is as safe as aspirin, and more effective at preventing recurrence of life-threatening blood clots in the legs ...

Dual antiplatelet Tx similar to aspirin post-CABG in diabetes

January 10, 2017
(HealthDay)—For post-coronary artery bypass grafting (CABG) patients with diabetes, cardiovascular and bleeding outcomes do not differ significantly with use of dual antiplatelet therapy (DAPT) versus aspirin, according ...

Study details death risks associated with long-term antiplatelet therapy

March 15, 2017
A study by a multi-institutional research team has tracked the long-term incidence of death following ischemic and bleeding events occurring in patients more than one year after placement of a coronary stent. Their study ...

New study finds antithrombotic therapy has no benefit for low-risk atrial fibrillation patients

March 17, 2017
Findings from a large, community-based study show that antithrombotic therapy doesn't decrease low-risk atrial fibrillation patients' risk of suffering a stroke within five years. In fact, researchers found that low-risk ...

Study reports progress in preventing bleeding in atrial fibrillation

November 14, 2016
A new study led by clinician-researchers at Beth Israel Deaconess Medical Center (BIDMC) testing the safety and effectiveness of anticoagulant strategies for patients with atrial fibrillation who undergo stenting procedures ...

Continued aspirin treatment safe with partial nephrectomy

April 25, 2016
(HealthDay)—Continuing aspirin for chronic antiplatelet therapy is safe in patients undergoing laparoscopic partial nephrectomy, according to a study published in the April issue of The Journal of Urology.

Recommended for you

Daily egg consumption may reduce cardiovascular disease

May 21, 2018
People who consume an egg a day could significantly reduce their risk of cardiovascular diseases compared with eating no eggs, suggests a study carried out in China, published in the journal Heart.

Natural antioxidant bilirubin may improve cardiovascular health

May 18, 2018
Bilirubin, a yellow-orange pigment, is formed after the breakdown of red blood cells and is eliminated by the liver. It's not only a sign of a bruise, it may provide cardiovascular benefits, according to a large-scale epidemiology ...

New algorithm more accurately predicts life expectancy after heart failure

May 17, 2018
A new algorithm developed by UCLA researchers more accurately predicts which people will survive heart failure, and for how long, whether or not they receive a heart transplant. The algorithm would allow doctors to make more ...

New genes found that determine how the heart responds to exercise

May 17, 2018
A new study by researchers at Queen Mary University of London and University College London (UCL) has discovered 30 new gene locations that determine how the heart responds to and recovers from exercise.

Novel therapy inhibits complement to preserve neurons and reduce inflammation after stroke

May 16, 2018
A team of investigators at the Medical University of South Carolina (MUSC) has developed a novel therapy for ischemic (clot-caused) stroke and has shown in a preclinical model that it locally inhibits complement at and around ...

Greater burden of atrial fibrillation linked to higher stroke risk

May 16, 2018
Among people with intermittently recurring atrial fibrillation who are not taking anti-blood-clotting medications, those whose hearts were in abnormal rhythms longer were three times more likely to have strokes or other types ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.